JPMorgan Starts Jazz Pharmaceuticals (JAZZ) at Overweight, 'We see continued uptake of Epidiolex'
Tweet Send to a Friend
JPMorgan analyst Jessica Fye initiates coverage on Jazz Pharmaceuticals (NASDAQ: JAZZ) with a Overweight rating and a price target of ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
